BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BMRN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $11.70B
- Forward P/E
- 9.60
- EPS (TTM)
- -$0.10
- Dividend yield
- None
- 52-week range
- 49.26 – 70.98
- Day range
- 59.84 – 62.00
- Volume / Avg
- 6.06M / 2.35M
- Beta
- —
- Shares outstanding
- 193.69M
52-week range
BMRN stock today
On Nov 20, BMRN ended the session at $60.41, shedding $1.01 (1.64%), versus the S&P 500's 3.70% decline. Volume was 2.6x the average at 6.06M shares, a sign of unusually heavy trading. Shares are 14.9% below their 52-week high of $70.98, set on Aug 12, 2026 and 22.6% above the 52-week low of $49.26, in the middle of the past year's range.
BMRN is up 1.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 10.5%. BioMarin Pharmaceutical has posted a net loss over the last twelve months (EPS of -$0.10), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About BioMarin Pharmaceutical
Company profileBioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Alexander Hardy
- Headquarters
- San Rafael, CA
- Employees
- 3,221
- IPO year
- 1999
- Website
- biomarin.com
Financial highlights
Full financialsIn fiscal 2025, BioMarin Pharmaceutical generated $3.22 billion in revenue, up 12.9% from fiscal 2024, its 4th consecutive year of revenue growth. Net income was $348.9 million (-18.3% year over year), for a net margin of 10.8% versus a median of 6.9% in the prior 5 years. Gross margin was 77.7% (down from 79.7%) and operating margin 12.7%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B |
| Growth | +12.87% | +17.97% | +15.42% | +13.53% | -0.76% |
| Net income | $348.90M | $426.86M | $167.65M | $141.56M | $-64.08M |
| EPS (diluted) | $1.80 | $2.21 | $0.87 | $0.75 | $-0.35 |
Analyst forecast
ForecastConsensus (28 analysts)
buy
Avg. price target
$90.30+49.48%
- Strong buy 5
- Buy 16
- Hold 7
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 2, 2026
- EPS actual vs est.
- $-0.08 vs $-0.30
- Surprise
- +73.33%
BMRN news
All BMRN news- BioMarin Pharmaceutical Inc. (BMRN) Presents at Jefferies London Healthcare Conference - SlideshowSeeking Alpha
- BioMarin Pharmaceutical Bets on Amicus Growth as VOXZOGO Competition Concerns MountNasdaq
- BioMarin Pharmaceutical Inc. (BMRN) Presents at Jefferies Global Healthcare Conference 2026 TranscriptSeeking Alpha
- BioMarin Pharmaceutical Sees $2.6 Billion Sales Potential in Amicus Drugs as VOXZOGO Expansion LoomsNasdaq
- BioMarin Pharmaceutical Inc. (BMRN) Presents at UBS Global Biopharma Conference 2026 TranscriptSeeking Alpha
- BioMarin Pharmaceutical Hits $1 Billion Revenue Milestone, Advances Rare-Disease PipelineNasdaq
- BioMarin Pharmaceutical Inc. (BMRN) Presents at Stifel 2026 Healthcare Conference 2026 TranscriptSeeking Alpha
- BioMarin Pharmaceutical Inc. 2026 Q3 - Results - Earnings Call PresentationSeeking Alpha
BioMarin Pharmaceutical peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RDYDr. Reddy's Laboratories Ltd | 14.89 | +0.40% | $12.41B | vs BMRN |
| ELANElanco Animal Health Incorporated | 25.74 | -2.09% | $12.87B | vs BMRN |
| TGTXTG Therapeutics Inc. | 63.34 | -2.37% | $9.57B | vs BMRN |
| JAZZJazz Pharmaceuticals plc | 230.26 | -2.62% | $14.78B | vs BMRN |
| BBIOBridgeBio Pharma Inc. | 76.03 | -2.75% | $14.81B | vs BMRN |
| SYRESpyre Therapeutics Inc. | 93.47 | -4.26% | $8.88B | vs BMRN |
| MDGLMadrigal Pharmaceuticals Inc. | 379.10 | -4.45% | $8.81B | vs BMRN |
| PRAXPraxis Precision Medicines Inc. | 300.43 | -3.37% | $8.40B | vs BMRN |
Indexes, lists and sector
BioMarin Pharmaceutical stock FAQ
What is BioMarin Pharmaceutical's stock price today?
BMRN last traded at $60.41 as of Nov 20, 4:00 PM EST, down 1.64% on the day. Prices are delayed at least 15 minutes.
Who is BioMarin Pharmaceutical's CEO?
Mr. Alexander Hardy is the chief executive officer of BioMarin Pharmaceutical Inc., which has about 3,221 employees.
What is the BMRN 52-week high?
The 52-week high for BMRN is $70.98 and the 52-week low is $49.26. The stock is currently 14.9% below its high.